BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823-826. [PMID: 21362710 DOI: 10.1136/ard.2010.140822] [Cited by in Crossref: 125] [Cited by in F6Publishing: 93] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Saougou I, Markatseli TE, Papagoras C, Kaltsonoudis E, Voulgari PV, Drosos AA. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine 2013;80:34-7. [PMID: 22575067 DOI: 10.1016/j.jbspin.2012.03.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
2 Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5. [PMID: 28492050 DOI: 10.1016/j.ijwd.2016.12.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
3 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität. J Dtsch Dermatol Ges 2021;19:1092-117. [PMID: 34288473 DOI: 10.1111/ddg.14507_g] [Reference Citation Analysis]
4 Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2020;59:1808-17. [PMID: 32118278 DOI: 10.1093/rheumatology/keaa064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
5 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. WJR 2015;5:50. [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
6 Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
7 Tsao NW, Sayre EC, Hanley G, Sadatsafavi M, Lynd LD, Marra CA, De Vera MA. Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Ann Rheum Dis 2018;77:869-74. [PMID: 29496718 DOI: 10.1136/annrheumdis-2018-213023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
8 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. [PMID: 27156434 DOI: 10.1016/s0140-6736(16)30173-8] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 551] [Article Influence: 277.4] [Reference Citation Analysis]
9 Simon PC, Vallano A. [Anti-tumor necrosis factor-α medications and pregnancy]. Med Clin (Barc) 2013;141:257-9. [PMID: 23702347 DOI: 10.1016/j.medcli.2013.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Nast A, Altenburg A, Augustin M, Boehncke WH, Härle P, Klaus J, Koza J, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Schlaeger M, Schmid-Ott G, Sebastian M, von Kiedrowski R, Weberschock T, Dressler C. German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations. J Dtsch Dermatol Ges 2021;19:1092-115. [PMID: 34288477 DOI: 10.1111/ddg.14507] [Reference Citation Analysis]
11 Mekinian A, Cohen J, Alijotas-reig J, Carbillon L, Nicaise-roland P, Kayem G, Daraï E, Fain O, Bornes M. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? Am J Reprod Immunol 2016;76:8-28. [DOI: 10.1111/aji.12493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 11.4] [Reference Citation Analysis]
12 Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis 2019;22:340-56. [PMID: 30816645 DOI: 10.1111/1756-185X.13510] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
13 Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35:501-515. [PMID: 22221203 DOI: 10.1111/j.1365-2036.2011.04967.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
14 Elkayam O, Pavelka K. Biologic registries in rheumatology: Lessons learned and expectations for the future. Autoimmunity Reviews 2012;12:329-36. [DOI: 10.1016/j.autrev.2012.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
15 Zhang J, Curtis JR. Considerations in using registry and health plan data for studying pregnancy in rheumatic diseases. Curr Opin Rheumatol 2014;26:315-20. [PMID: 24667289 DOI: 10.1097/BOR.0000000000000056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
16 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 15.5] [Reference Citation Analysis]
17 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Medicina Clínica 2016;147:352-60. [DOI: 10.1016/j.medcli.2016.05.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
19 Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6:105-107. [PMID: 23329988 DOI: 10.3315/jdcr.2012.1116] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
20 Louthrenoo W, Kasitanon N, Katchamart W, Aiewruengsurat D, Chevaisrakul P, Chiowchanwisawakit P, Dechanuwong P, Hanvivadhanakul P, Mahakkanukrauh A, Manavathongchai S, Muangchan C, Narongroeknawin P, Phumethum V, Siripaitoon B, Suesuwan A, Suwannaroj S, Uea-areewongsa P, Ukritchon S, Asavatanabodee P, Koolvisoot A, Nanagara R, Totemchokchyakarn K, Nuntirooj K, Kitumnuaypong T. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Int J Rheum Dis 2017;20:1166-84. [DOI: 10.1111/1756-185x.13130] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
21 De Simone C, Caldarola G, Moretta G, Piscitelli L, Ricceri F, Prignano F. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol 2019;154:305-14. [PMID: 31001966 DOI: 10.23736/S0392-0488.18.06255-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
22 Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019;22:357-75. [PMID: 30809944 DOI: 10.1111/1756-185X.13513] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
23 Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl) 2015;5:83-95. [PMID: 29387585 DOI: 10.2147/PTT.S82975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 2017;76:38-52. [PMID: 27913060 DOI: 10.1016/j.jaut.2016.11.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
25 Friedman S, McElrath TF, Wolf JL. Management of fertility and pregnancy in women with inflammatory bowel disease: a practical guide. Inflamm Bowel Dis. 2013;19:2937-2948. [PMID: 23945187 DOI: 10.1097/mib.0b013e3182a0ea6f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
26 Tada Y, Sakai M, Nakao Y, Maruyama A, Ono N, Koarada S. Placental transfer of tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1694-5. [PMID: 31329987 DOI: 10.1093/rheumatology/kez155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
27 Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GDV, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings From the American College of Rheumatology Reproductive Health Summit: The Management of Fertility, Pregnancy, and Lactation in Women With Autoimmune and Systemic Inflammatory Diseases: Pregnancy in Autoimmune and Systemic Inflammatory Diseases. Arthritis Care & Research 2015;67:313-25. [DOI: 10.1002/acr.22516] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
28 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 10.5] [Reference Citation Analysis]
29 Hernández MV, Sanmartí R, Cañete JD. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Expert Opin Drug Saf 2016;15:613-24. [PMID: 26927029 DOI: 10.1517/14740338.2016.1160054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
30 Park E, Kim H, Jung SM, Sung Y, Baek HJ, Lee J. The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus. J Rheum Dis 2020;27:4. [DOI: 10.4078/jrd.2020.27.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
31 Kiltz U, Braun J, Becker A, Chenot JF, Dreimann M, Hammel L, Heiligenhaus A, Hermann KG, Klett R, Krause D, Kreitner KF, Lange U, Lauterbach A, Mau W, Mössner R, Oberschelp U, Philipp S, Pleyer U, Rudwaleit M, Schneider E, Schulte TL, Sieper J, Stallmach A, Swoboda B, Winking M; DGRh., DEGAM., DWG., DVMB., DOG., DRG., DGMM., DGPMR/DGRW., Physio Deutschland., DDG., DGOOC., DGIM., DGOOC/DGORh., DGNC. [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations]. Z Rheumatol 2019;78:3-64. [PMID: 31784900 DOI: 10.1007/s00393-019-0670-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
32 Genest G, Spitzer KA, Laskin CA. Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy. J Rheumatol 2018;45:1109-15. [PMID: 29961692 DOI: 10.3899/jrheum.171152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
33 Shihab Z, Yeomans ND, De Cruz P. Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016;10:979-988. [PMID: 26755733 DOI: 10.1093/ecco-jcc/jjv234] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
34 Park EJ, Kim H, Jung SM, Sung YK, Baek HJ, Lee J. The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus. Korean J Intern Med 2020;35:41-59. [PMID: 31935319 DOI: 10.3904/kjim.2019.411] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Cañete JD, Hernández MV, Sanmartí R. Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy 2017;17:1089-103. [DOI: 10.1080/14712598.2017.1346078] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
36 Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol 2017;13:503-10. [PMID: 28569267 DOI: 10.1038/nrrheum.2017.81] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
37 Carnovale C, Parisi F, Battini V, Zavatta A, Cheli S, Cattaneo D, Gringeri M, Mosini G, Guarnieri G, Cammarata G, Cetin I. The use of biological agents in pregnant women affected by autoimmune disorders: Why we need more research of this neglected area. Pharmacol Res 2021;171:105786. [PMID: 34314858 DOI: 10.1016/j.phrs.2021.105786] [Reference Citation Analysis]
38 Ara M, Daudén E. Etanercept for the treatment of psoriasis. Expert Review of Dermatology 2014;8:357-72. [DOI: 10.1586/17469872.2013.814880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
39 Yeung J, Gooderham MJ, Grewal P, Hong CH, Lansang P, Papp KA, Poulin Y, Turchin I, Vender R. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg 2020;24:3S-14S. [PMID: 32500730 DOI: 10.1177/1203475420928376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf 2016;39:755-62. [PMID: 27282428 DOI: 10.1007/s40264-016-0431-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 16.8] [Reference Citation Analysis]
41 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
42 Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Seminars in Arthritis and Rheumatism 2015;45:351-6. [DOI: 10.1016/j.semarthrit.2015.06.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
43 Mekinian A, Cohen J, Kayem G, Carbillon L, Nicaise-roland P, Gaugler B, Darai E, Bornes M, Fain O. Fausses couches précoces récurrentes inexpliquées : quelle est la place de l’immunomodulation ? La Revue de Médecine Interne 2017;38:264-8. [DOI: 10.1016/j.revmed.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
44 Weber-schoendorfer C, Beck E, Tissen-diabaté T, Schaefer C. Leflunomide – A human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database. Reproductive Toxicology 2017;71:101-7. [DOI: 10.1016/j.reprotox.2017.04.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
45 Malviya G, Salemi S, Laganà B, Diamanti AP, D'Amelio R, Signore A. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs 2013;27:329-45. [PMID: 23558378 DOI: 10.1007/s40259-013-0021-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
46 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
47 Puchner A, Gröchenig HP, Sautner J, Helmy-Bader Y, Juch H, Reinisch S, Högenauer C, Koch R, Hermann J, Studnicka-Benke A, Weger W, Puchner R, Dejaco C. Immunosuppressives and biologics during pregnancy and lactation : A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation.Wien Klin Wochenschr. 2019;131:29-44. [PMID: 30643992 DOI: 10.1007/s00508-019-1448-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
48 Sato R, Ikuma M, Takagi K, Yamagishi Y, Asano J, Matsunaga Y, Watanabe H. Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in Japan. Medicine (Baltimore) 2015;94:e386. [PMID: 25569668 DOI: 10.1097/MD.0000000000000386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
49 Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810. [PMID: 26888948 DOI: 10.1136/annrheumdis-2015-208840] [Cited by in Crossref: 445] [Cited by in F6Publishing: 317] [Article Influence: 89.0] [Reference Citation Analysis]
50 Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci 2014;10:1175-85. [PMID: 25624856 DOI: 10.5114/aoms.2014.47827] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 14.5] [Reference Citation Analysis]
51 Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation. Journal of the American Academy of Dermatology 2014;70:401.e1-401.e14. [DOI: 10.1016/j.jaad.2013.09.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 56] [Article Influence: 14.0] [Reference Citation Analysis]
52 Krause ML, Makol A. Management of rheumatoid arthritis during pregnancy: challenges and solutions. Open Access Rheumatol 2016;8:23-36. [PMID: 27843367 DOI: 10.2147/OARRR.S85340] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
53 Grotting LA, Papaliodis GN. A Review of the Course and Treatment of Non-Infectious Uveitis during Pregnancy. Semin Ophthalmol 2017;32:75-81. [PMID: 27805464 DOI: 10.1080/08820538.2016.1228402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 O’neill I, Scully C. Biologics in oral medicine: principles of use and practical considerations: Biologics use and practical considerations. Oral Diseases 2012;18:525-36. [DOI: 10.1111/j.1601-0825.2012.01919.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
55 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
56 Uyaroglu OA, Seyhoglu E, Erden A, Kilic L, Karadag O, Akdogan A, Bilgen SA, Ertenli AI, Kiraz S, Kalyoncu U. Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor-α biologics: real-life results from a single-centre cross-sectional study. Rheumatol Int 2020;40:1501-7. [PMID: 31993731 DOI: 10.1007/s00296-020-04518-3] [Reference Citation Analysis]
57 Zavada J, Dixon WG, Askling J; for the EULAR Study group on Longitudinal Observational Registers and Drug Studies. Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: a EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis 2014;73:628-628. [DOI: 10.1136/annrheumdis-2013-204102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
58 Maccari F, Fougerousse AC, Esteve E, Frumholtz L, Parier J, Hurabielle C, Cassius C, Taieb C; GEM RESOPSO and the AJDerm. Crossed looks on the dermatologist's position and the patient's preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study. J Eur Acad Dermatol Venereol 2019;33:880-5. [PMID: 30633377 DOI: 10.1111/jdv.15423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
59 Prasad JD, Gunn KC, Davidson JO, Galinsky R, Graham SE, Berry MJ, Bennet L, Gunn AJ, Dean JM. Anti-Inflammatory Therapies for Treatment of Inflammation-Related Preterm Brain Injury. Int J Mol Sci 2021;22:4008. [PMID: 33924540 DOI: 10.3390/ijms22084008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Bangsgaard N, Rørbye C, Skov L. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. Am J Clin Dermatol 2015;16:389-98. [PMID: 26149091 DOI: 10.1007/s40257-015-0137-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Bazzani C, Andreoli L, Agosti M, Nalli C, Tincani A. Antirheumatic drugs and reproduction in women and men with chronic arthritis. RMD Open 2015;1:e000048. [PMID: 26557371 DOI: 10.1136/rmdopen-2015-000048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
62 Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol 2021;12:621247. [PMID: 34122062 DOI: 10.3389/fphar.2021.621247] [Reference Citation Analysis]
63 Barenbrug L, Groen MT, Hoentjen F, van Drongelen J, Reek JMPAVD, Joosten I, de Jong EMGJ, van der Molen RG. Pregnancy and neonatal outcomes in women with immune mediated inflammatory diseases exposed to anti-tumor necrosis factor-α during pregnancy: A systemic review and meta-analysis. J Autoimmun 2021;122:102676. [PMID: 34126302 DOI: 10.1016/j.jaut.2021.102676] [Reference Citation Analysis]
64 Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2012;91:30-43. [PMID: 22166850 DOI: 10.1038/clpt.2011.278] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 10.6] [Reference Citation Analysis]
65 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Gómez-puerta J, Cervera R. Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome? Lupus 2013;22:754-5. [DOI: 10.1177/0961203313490433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
67 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
69 Rustin M. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data: Long-term safety of biologics for moderate-to-severe plaque psoriasis. British Journal of Dermatology 2012;167:3-11. [DOI: 10.1111/j.1365-2133.2012.11208.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
70 Kim SC, Hernandez-Diaz S. Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol. 2014;66:246-249. [PMID: 24504795 DOI: 10.1002/art.38258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
71 Rom AL, Wu CS, Olsen J, Kjaergaard H, Jawaheer D, Hetland ML, Vestergaard M, Mørch LS. Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study. Arthritis Rheumatol 2014;66:3265-73. [PMID: 25393524 DOI: 10.1002/art.38874] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
72 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
73 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
74 Bröms G, Kieler H, Ekbom A, Gissler M, Hellgren K, Lahesmaa-Korpinen AM, Pedersen L, Schmitt-Egenolf M, Sørensen HT, Granath F. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020;29:316-27. [PMID: 32020767 DOI: 10.1002/pds.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
75 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
76 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
77 Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T, Naganuma M, Hida N. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res. 2016;14:139-145. [PMID: 27175114 DOI: 10.5217/ir.2016.14.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
78 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 9.1] [Reference Citation Analysis]
79 Natsumi I, Matsukawa Y, Miyagawa K, Kodaira H, Tanaka T, Horikoshi A, Takeuchi J, Takei M, Maejima M, Akimoto J. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int 2013;33:2433-5. [DOI: 10.1007/s00296-012-2433-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Reinisch W, Van Assche G, Befrits R, Connell W, D'haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis 2012;6:248-58. [DOI: 10.1016/j.crohns.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
81 Atzeni F, Sarzi-puttini P. Twelve years’ experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. Expert Review of Clinical Immunology 2014;8:213-22. [DOI: 10.1586/eci.12.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
82 Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics 2015;9:1-6. [PMID: 25670881 DOI: 10.2147/BTT.S68949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
83 Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev 2015;14:651-8. [PMID: 25870941 DOI: 10.1016/j.autrev.2015.04.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
84 van den Brandt S, Zbinden A, Baeten D, Villiger PM, Østensen M, Förger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 2017;19:64. [PMID: 28320445 DOI: 10.1186/s13075-017-1269-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
85 Nasef NA, Ferguson LR. Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res. 2012;160:65-83. [PMID: 22687963 DOI: 10.1016/j.trsl.2011.12.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
86 Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy. Clinical Gastroenterology and Hepatology 2016;14:234-241.e5. [DOI: 10.1016/j.cgh.2015.08.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
87 Lau CS, Chia F, Harrison A, Hsieh T, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo S, Nash P, Ng CT, Park S, Suryana BPP, Suwannalai P, Wijaya LK, Yamamoto K, Yang Y, Yeap SS. APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015;18:685-713. [DOI: 10.1111/1756-185x.12754] [Cited by in Crossref: 84] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
88 Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A. Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan. Mod Rheumatol 2016;26:667-71. [PMID: 26873562 DOI: 10.3109/14397595.2016.1147405] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 9.4] [Reference Citation Analysis]
89 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clinic Rev Allerg Immunol 2017;53:40-53. [DOI: 10.1007/s12016-016-8596-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 17.5] [Reference Citation Analysis]
90 Ergaz Z, Bar-Oz B, Vainer GW, Abu-Leil S, Simanovsky N, Diav-Citrin O. Congenital fulminant Kaposiform hemangioendothelioma of the leg. Reprod Toxicol. 2014;50:1-3. [PMID: 25277314 DOI: 10.1016/j.reprotox.2014.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Yiu ZZ, Griffiths CE, Warren RB. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. Br J Dermatol. 2014;171:485-491. [PMID: 24749725 DOI: 10.1111/bjd.13060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
92 Kurizky PS, Ferreira Cde C, Nogueira LS, Mota LM. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. An Bras Dermatol 2015;90:367-75. [PMID: 26131868 DOI: 10.1590/abd1806-4841.20153113] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
93 Viktil K, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers. Scandinavian Journal of Rheumatology 2012;41:196-201. [DOI: 10.3109/03009742.2011.626442] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]